Plain-English translation of NCT06633900 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether naltrexone, given as a monthly injection, can help prevent opioid overdose in people living with HIV or at risk for HIV who use stimulants like cocaine or methamphetamine. The medication blocks the effects of opioids, which can reduce the risk of overdose if someone is exposed to them. Researchers want to see if this approach is safe, acceptable to participants, and actually works.
Many people who use stimulants are also exposed to opioids, particularly fentanyl, which is a leading cause of overdose deaths. This medication has been used to treat opioid addiction, but researchers want to learn if it can be used as a preventive tool—like a shield—for people at high risk of accidental opioid exposure.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of two groups. One group will receive the monthly injection for six months, while the other group will receive standard overdose prevention supplies and nasal naloxone. You'll come in for monthly visits over 24 weeks, plus a final visit at 32 weeks. At each visit, the research team will check on your health, test for opioid and stimulant use (using urine samples and hair samples), and monitor how well the treatment is working and any side effects.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States